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SDX group, their average costs per hospitalization were
less ($8,145 versus $18,617) in part due to shorter ALOS
(7.9 versus 14.3 days). Costs due to rehabilitation (8%
versus 3%) and other services including surgical care and
cast room (20% versus 5%) were higher in the SDX
group, presumably due to 85% of these patients receiving
acute rehabilitation, fractures, or falls related diagnoses.
For both groups, nursing care was the major cost driver
(73% and 58%). Services including radiology, labora-
tory, pharmacy, EKG, EEG, and EMG totaled 19% and
14% of the PDX and SDX group costs, respectively.
CONCLUSION: The study found that most patients
were admitted for the treatment of Parkinson’s disease–
related (secondary) diagnoses rather than for primary di-
agnosis of Parkinson’s disease. Providing better care at
home and applying appropriate safety precautions may
potentially impact a portion of these admissions and re-
duce associated resource use.
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OBJECTIVE: We estimated savings in the cost of caring
for Alzheimer’s disease patients during 6 months, 1 year,
and 2 years treatment with rivastigmine. An intermediate
objective was to estimate the relationship between dis-
ease progression and institutionalization.
METHODS: We assessed the relationship between Mini-
Mental State Examination (MMSE) score and institutional-
ization using a piecewise Cox proportional hazard model.
To estimate cost savings from treatments lasting 6 months,
1 year, and 2 years, estimates of the probability of institu-
tionalization were integrated with data from a 6-month,
Phase III clinical trial of rivastigmine and a hazard model
of disease progression.
RESULTS: Our data suggest that savings in the overall
cost of caring for patients with mild and moderate AD
can be as high as $4839.00 per patient after 2 years treat-
ment. Further, the probability of institutionalization in-
creases steadily as MMSE score falls. Among our study
subjects age, race, level of education, and marital status
were significant predictors of institutionalization, while
gender had little effect.
CONCLUSION: Using rivastigmine in treating Alzhe-
imer’s disease results in a delay in disease progression for
patients who begin treatment during the mild or moder-
ate stages of the disease. By delaying the probability that
a patient will be institutionalized, the cost of caring for
AD patients can be significantly reduced.
 
ND3
 
AN OUTCOMES MEASURE FOR 
NON-INSTITUTIONALIZED 
SCHIZOPHRENIC CONSUMERS
Barr JT
 
1
 
, Schumacher GE
 
1
 
, Mason EJ
 
1
 
, Ohman SM
 
1
 
, Hanson A
 
2
 
1
 
Northeastern University, Boston, MA, USA; 
 
2
 
Massachusetts 
Division of Medical Assistance, Boston, MA, USA
OBJECTIVE: We developed and then validated a self-
administered health-related quality of life survey for indi-
viduals with schizophrenia living in the community as
part of the Schizophrenia Outcomes Assessment Project
(SOAP).
METHODS: Fifteen hundred adult consumers with schizo-
phrenia (61% male) were recruited from five states (AZ,
MA, SC, WA, WI). Consumers completed four adminis-
trations of a 51-item survey assessment in 3 months. A
staff version of consumer status was also completed at
each administration.
RESULTS: Factor analysis, based on 1382 consumers
who answered all 51 items, supports eight factors: satis-
faction, self-concept, work/role, mental health, interper-
sonal, medication effects, activities of daily living, and
physical function. The combined score of the instrument
ranges from a low of 51 to a high of 204 with a popula-
tion mean of 150.6  20.2. Cronbach alpha of the
51-item survey is 0.9242 with all but one of the eight fac-
tors being over 0.700 (medication effects was 0.624).
Each item had a stronger correlation with its factor score
with that item removed than with other factors. Face and
content validity were established by an expert panel and
consumers. Convergent validity was established by com-
paring consumers’ global assessment of their status for
each factor to the companion actual factor scores; con-
gruence was significant (p  0.0001). Divergent validity
was established by comparing staffs’ placement of the
consumers into four levels of functionality for each of the
eight factors. Except for the medication effects factor, the
association between staff assessment and consumer fac-
tor scores was significant (p  0.0001).
CONCLUSION: The SOAP-51 is a valid and reliable
health-related quality of life instrument for use in a popu-
lation of individuals with schizophrenia living in the
community.
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Depression is a public health problem with a lifetime preva-
lence estimate over 17% and the second leading cause
of disease burden worldwide. Despite the existence of
